Blueprint Medicines Corp (NAS:BPMC)
$ 96.53 -1.09 (-1.12%) Market Cap: 6.13 Bil Enterprise Value: 5.94 Bil PE Ratio: 0 PB Ratio: 19.54 GF Score: 81/100

Q4 2019 Blueprint Medicines Corp Earnings Call Transcript

Feb 13, 2020 / 01:30PM GMT
Release Date Price: $63.81 (-1.44%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Fourth Quarter 2019 Blueprint Medicines Conference Call. (Operator Instructions)

And I would now like to hand the conference over to your speaker today, Kristin Hodous. Thank you, and please go ahead, ma'am.

Kristin Hodous
Blueprint Medicines Corporation - Senior Manager of IR

Thank you, operator. Good morning, everyone. This is Kristin Hodous of Blueprint Medicines, and welcome to Blueprint Medicines' Fourth Quarter and Full Year 2019 Financial and Operating Results Conference Call. This morning, we issued a press release which outlines the topics that we plan to discuss today. You can access the press release as well as the slides that we'll be reviewing today by going to the Investors section of our website at www.blueprintmedicines.com.

Today on our call, Jeff Albers, our Chief Executive Officer, will discuss Blueprint Medicines' fourth quarter and full year 2019 business highlights; Dr. Andy

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot